Skip to Content

Sanofi SA ADR SNY Stock Quote

| Rating as of


Last close prices updated as of Feb 07, 2023, 4:08 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 45.86
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Blend
  • Day Range 46.21  –  47.06
  • Year Range 36.91  –  58.10
  • Market Cap 117.8148 Bil
  • Volume / Avg 2.4 Mil /  2.5 Mil
  • Price / Sales 2.35
  • Price / Book 1.46
  • Forward Div Yield 3.81%
  • Trailing Div Yield 4.35%

Morningstar‘s Stock Analysis SNY

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Undervalued Sanofi Posts Steady Q4 With Strong Dupixent Sales Offsetting Mature Drug Declines

Damien Conover Sector Director

Analyst Note

| Damien Conover |

Sanofi reported fourth-quarter results and issued 2023 guidance largely in line with our expectations, and we don’t expect any major fair value estimate changes based on the update. We continue to view the stock as undervalued, with the market not fully appreciating the firm’s ability to drive cash flows from immunology drug Dupixent and redeploy the gains toward successful new drug development. While the Dupixent sales gains (up 42% to EUR 2.4 billion) were impressive, the ability to drive successful drug development has been less robust recently. Nevertheless, with patent protection on Dupixent for almost another decade, we believe Sanofi will have increasing success with its earlier-stage drug pipeline, partly based on a shift toward more innovative drugs, reinforcing the firm’s wide moat.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics SNY

Company Profile SNY

Business Description

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

54, Rue La Boetie
Paris, 75008, FRA
Industry Drug Manufacturers - General
Employees 86,000

Related Articles SNY

FAQs for Sanofi SA ADR Stock

Yes. SNY has a forward dividend yield of 3.81%. See SNY’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

SNY’s market cap is 117.81 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

SNY’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

SNY’s price/sales is 2.35.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

SNY’s price/forward earnings is 9.69.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

SNY’s price/book is 1.46.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See SNY’s valuation ratios compared to the Market Index.

SNY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare SNY’s historical performance against its industry peers and the overall market.